Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells
Mark E. Gurney(W.E. Upjohn Institute for Employment Research), Michael O’Dwyer(Ollscoil na Gaillimhe – University of Galway)
Cited by 37
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k